argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe,…
$927.21+3.63%
报价 2026-11-06
市值
$58.31B
EV
$61.97B
PE (TTM)
38.2x
预期 PE
–
52 周区间距高点 -12.4%
$663.93$1,058.90
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ARGXargenx SE | $58.31B | +3.6% | – | 89.9% | 38.2x | 39.0x | 58.5x | |
| VRTXVertex Pharmaceuticals Incorporated | $138.67B | +0.8% | +8.8% | 86.3% | 29.0x | 23.5x | 43.4x | |
| MRNAModerna, Inc. | $101.48B | +5.3% | +9.3% | -12.6% | – | – | – | |
| REGNRegeneron Pharmaceuticals, Inc. | $93.54B | +0.2% | +11.7% | 85.8% | 19.8x | 15.1x | 26.6x | |
| GMABGenmab A/S | $32.98B | +1.7% | – | 39.9% | 45.6x | 28.5x | 41.3x | |
| RPRXRoyalty Pharma plc | $29.97B | -0.4% | +14.8% | 100% | 25.6x | 17.1x | 12.1x | |
| ROIVRoivant Sciences Ltd. | $28.08B | +6.2% | – | 81.2% | – | – | – | |
| INSMInsmed Incorporated | $25.1B | +5.2% | +191.4% | 84.3% | – | – | – | |
| INCYIncyte Corporation | $24.39B | +1.4% | +12.9% | 91.8% | 13.9x | 8.5x | 17.9x | |
| 同行中位数 | – | – | +12.3% | 85% | 25.6x | 17.1x | 26.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。